Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Izuchukwu F. Okpalanwaka; Elizabeth A. Daugherity; Amanda L. McCormick; Trevor S. Anderson; Savanna L. Smith; Caryn Lawrence; Duke Appiah; Devin B. Lowe

doi:10.1158/1535-7163.29760635

August 1, 2025

Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Bispecific antibody treatment enhances CD8+ T cell infiltration and apoptosis in colon cancer.
KEY EVIDENCE: Improved outcomes were observed in the CT26 tumor microenvironment after REG/bsAb therapy.
APPROACH: The study analyzed changes in T cell behavior following treatment with regorafenib and a bispecific antibody.
SIGNIFICANCE: These findings indicate a potential strategy to increase the effectiveness of regorafenib in colon cancer treatment.

Implication

Supplementary Figure illustrates enhanced CD8+ T cell infiltration and apoptosis in colon cancer, suggesting bispecific antibodies boost regorafenib efficacy.

Abstract

Supplementary Figure 5 details improved CD8+ T cell infiltration and apoptosis in the CT26 TME after REG/bsAb treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Okpalanwaka et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d0254 https://doi.org/10.1158/1535-7163.29760635

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 5 from A PD-L1/CD3 Bispecific Antibody Enhances the Antitumor Effects of Regorafenib against Colon Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading